UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

July 1416, 2019

Date of Report (date of earliest event reported)

AirXpanders, Inc.

(Exact name of Registrant as specified in charter)

Delaware

000-55781

20-2555438

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I. R. S. Employer

Identification No.)

3047 Orchard Parkway, San Jose, CA, 95134

(Address of principal executive offices)

Registrant's telephone number, including area code: (650) 390-9000

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act: None

Item 82.0105 - ~~Other~~Costs ~~Events~~Associated with Exit or Disposal Activities.

~~AirXpanders~~On ~~has~~July ~~received~~16, ~~announced~~2019, ~~that~~the Company announced it had ~~received~~initiated ~~U.S.~~an ~~Food~~organizational ~~and~~restructuring. The ~~Drug~~Company ~~Administration~~expects ~~(FDA)~~the ~~510(k)~~restructuring ~~clearance~~ to ~~market~~include aan ~~smooth~~organizational ~~shell~~resizing, ~~version~~representing ofan ~~the~~immediate ~~AeroForm~~reduction ~~Tissue~~of ~~Expander~~approximately in80% ~~the~~of ~~United States. On June 15, 2019 (Australia time),~~ the Company’s ~~issued~~workforce, awith ~~press~~further ~~release~~reductions ~~regarding~~planned for the ~~receipt~~near offuture. The ~~the~~Company ~~approval.~~is ~~The~~unable ~~full~~to ~~text~~estimate ofany ~~the~~restructuring ~~press~~charges ~~release~~it ismay ~~attached~~incur as ~~Exhibit~~a ~~99.1~~result toof this ~~Current Report on Form 8-K~~restructuring.

Item 8.01 - Other Events.

On July 16, 2019, the Company announced it is notifying customers that it is ceasing sales of all products immediately, and will not be providing customer service or sales support after Thursday, July 18, 2019. The Company anticipates filing a petition for relief under chapter 7 of Title 11 of the United States Code no later than July 26, 2019.

Item 9.01 - Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 15, 2019		AIRXPANDERS, INC.
Dated: July 16, 2019		AIRXPANDERS, INC.
		/s/Frank Grillo
		Frank Grillo President and Chief Executive Officer
		Duly Authorized Officer
		(Duly Authorized Officer)

Filing Compare · AIRXPANDERS INC